Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2026)

Harmony Biosciences Holdings has disclosed Revenue across 7 years of filings, most recently posting $215.4 million for Q1 2026.

• Revenue for Q1 2026 came in at $215.4 million, up 16.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $899.1 million (up 20.71% YoY), and the FY2025 annual result was $868.5 million, up 21.51% from the prior year.
• Revenue came in at $215.4 million for Q1 2026 at Harmony Biosciences Holdings, down from $243.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $243.8 million in Q4 2025 to a low of $85.3 million in Q1 2022.
• The 5-year median for Revenue is $168.4 million (2023), against an average of $165.8 million.
• Across the five-year window, Revenue surged 45.18% in 2022 and increased 16.01% in 2025, its largest moves.
• Harmony Biosciences Holdings' Revenue stood at $128.3 million in 2022, then jumped by 31.26% to $168.4 million in 2023, then grew by 19.51% to $201.3 million in 2024, then rose by 21.12% to $243.8 million in 2025, then decreased by 11.65% to $215.4 million in 2026.
• The last three Revenue figures came in at $215.4 million (Q1 2026), $243.8 million (Q4 2025), and $239.5 million (Q3 2025), per Business Quant data.